Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

BioMarin Hypertension Candidate Fails Phase II Endpoint

This article was originally published in The Pink Sheet Daily

Executive Summary

Firm says Phase III phenylketonuria candidate, which has same active ingredient, not impacted by results.
Advertisement

Related Content

BioMarin Licenses UCSF Technology To Address Cause of Cystic Fibrosis
BioMarin Licenses UCSF Technology To Address Cause of Cystic Fibrosis
BioMarin Submits Kuvan For Phenylketonuria
BioMarin Submits Kuvan For Phenylketonuria
BioMarin Begins Phase II Study Of 6R-BH4 For Sickle Cell Disease
BioMarin Begins Phase II Study Of 6R-BH4 For Sickle Cell Disease
BioMarin Anticipates FDA Approval Of Phenoptin In Late 2007
BioMarin Anticipates FDA Approval Of Phenoptin In Late 2007

Topics

Advertisement
UsernamePublicRestriction

Register

PS065654

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel